UKRAINS'KYI VISNYK PSYKHONEVROLOHII

The Scientific and Practical Journal of Medicine
ISSN 2079-0325(p)
DOI 10.36927/2079-0325
Home » Archive of numbers » 2011 » Volume 19, issue 1 (66) » The possibility of achieving concomitant cognitive and anxiolytic eff ects as a new direction pharmacotherapy angioneurology

The possibility of achieving concomitant cognitive and anxiolytic eff ects as a new direction pharmacotherapy angioneurology

Authors

Type of Article

  • Scientific Article

In the Section

  • DIAGNOSIS AND TREATMENT OF NEUROLOGICAL DISORDERS

Key words

Index UDK:
  • 616.8—008.861—008.46:615.03:001.8

Abstract

One of the leading problems of modern neuroscience is early diagnosis and eff ective pharmacotherapy of the initial stages of cognitive disorders. Therefore, special interest causes the Ukrainian pharmaceutical market innovative domestic product Membraton production company Farkos
Membraton is a unique instrument and is a coordinating chelate compound gamma-aminobutyric acid (GABA) and gluconic acid with the inclusion of ion Mg2+, i. e. gamma-aminobutirato-Mg(II)- gluconate. Membraton contributes to the normalization of focal neurological symptoms, shows a moderate inducing eff ect, reduces the formation of perivascular edema, i. e., has a complex neuroprotective eff ect in cerebral circulatory disorders

Virtually no side eff ects (except in cases of individual intolerance) suggests the high degree of safety of the drug, allowing reception of his patients of all age groups, as well as during pregnancy and lactation, when the appointment of the vast majority of neuropharmacological funds should be excluded.
So today Membraton be regarded as one of the most promising neuropharmacological tools with nootropic, neurometabolic, antiasthenic and anxiolytic eff ects in clinical practice.

Pages

  • 5-8

Year / Issue

Download PDF

References

  1. Bachinskaya N.Y. Syndrome of mild cognitive decline in the elderly / N.Y. Bachinskaya // Journal of the Academy of Medical Sciences of Ukraine. 2004, Vol. 10, No. 3, pp. 555-562.
  2. Burchinsky S.G. Nootropics: classification, mechanisms of action, comparative characterization of pharmacological properties. Kiev, 2004. 21 с.
  3. Burchinsky, S. G. The problem of magnesium deficiency in the body: methods of pharmacological correction / S. G. Burchinsky // Zdorov'ya Ukrainy. - 2004. - № 18. - С. 27.
  4. Burchinsky, S. G. Neuroleptics in pharmacotherapy of anxiety disorders in cerebrovascular pathology / S. G. Burchinsky // Ibidem. - 2008. - № 5/1. - С. 48.
  5. Voloshyn P.V. Vascular dementia / Voloshyn P.V., Mishchenko T.S., Dmitrieva O.V. // Art of treatment. - 2004. - No. 5. - P. 36-39.
  6. Voronina, T. A. Nootropic drugs, achievements and prospects / Voronina T. A., Seredenin S. B. // Exp. clin. pharmacol. B. // Exp. klin. pharmakol. - 1998. - № 4. - С. 3-9.
  7. Features of the depressive syndrome in patients with ischemic stroke [Gusev E. I., Gecht A. B., Bogolepova A. N., et al] // Journal of Neurol. psychiat. - Appendix. Stroke. - 2001. - Vol. 3. - С. 28-31.
  8. Kryzhanovsky, G. N. Dysregulation pathology / G. N. Kryzhanovsky - Moscow: Medicine, 2002. - С. 18-78.
  9. Interaction of new non-doping ergogenic agents with phospholipid monolayer membranes / [Lyakhov A. M., Koval I. V., Kutnyak V. P. et al.] // Sport. med. - 2005. - № 2. - С. 103-105.
  10. Ostrovskaya, R. U. Nootropic properties of derivatives of gammaaminobutyric acid / R. U. Ostrovskaya, S. S. Trofimov // Bul. Experim. biol. med. - 1984. - № 12. - С. 170-172.
  11. Preobrazhenskaya, I. S. Age-related cognitive dysfunction: diagnosis and treatment / I. S. Preobrazhenskaya, N. N. Yakhno // Journal of Neurology and Psychiatry. С. S. Korsakov. - 2006. - Т. 106, № 11. - С. 33-38.
  12. To the question of the pathogenesis of post-stroke depression / [Filavoda E. G., Dobrovolskaya L. E., Posokhov S. I., et al.] // Ibid. - When lying. Stroke. - 2002. - Vol. 7. - С. 22-27.
  13. Altura, B. M. Importance of Mg in physiology and medicine and the need for ion selective electrodes / B. M. Altura // Scand. J. Clin. Lab. Invest. — 1994. — V. 54, suppl. 217. — P. 5—9.
  14. Andrews, O. L. Psychopathology for General Practitioners / Andrews O. L., Stewens T. R., Cordero P. — Cambridge: Cambridge Univ. Press, 2005. — 426 p.
  15. Bartus, R. T. Cholinergic hypothesis of memory disorders / Bar tus R. T., Dean P. K., Beer T. // Science. — 1982. — V. 217. — P. 408—417.
  16. Colden, A. T. Anxiety Disorders / A. T. Colden. In: Modern Aspects in Biological Psychiatry. — N. Y.: CRC Press, 2003. — P. 184—198.
  17. Davis, H. S. Conceptualization of mild cognitive impairment: a review / H. S. Davis, K. Rockwood // Int. J. Geriatr. Psychiat. — 2004. — V. 19. — P. 313—319.
  18. Ebel, H. Magnesium metabolism: a review / H. Ebel, T. Gunther // J. Clin. Chem. & Clin. Biochem. — 1998. — V. 18. — P. 257—270.
  19. Ellergast, J. P. Gamma-aminobutyric acid — mediated neurophysiological effects in the central nervous system / J. P. Ellergast. In: Brain neurophysiology. — Chicago: Illinois Univ. Press, 2000. — P. 497—530.
  20. Glowania, A. Administration of magnesium compounds in medical practice / A. Glowania, I. Glowania // Med. Metabol. — 2000. — V. 4. — P. 37—44.
  21. An update on physiological, clinical and analytical aspects / [Saris N. E. L., Mervaala E., Karppanen H. et al.] // Clin. Chim. Acta. — 2000. — V. 249. — P. 1—26.
  22. Schatzberg, A. F. Textbook of Psychopharmacology / A. F. Schatzberg, C. B. Nemeroff. — Washington : Amer. Psychiat. Press, 1998. — 643 p.
  23. Spenser K. A. Assessment of depression in patients with brain pathology: the case of stroke / K. A. Spenser // Psychol. Bull. — 1997. — V. 122. — P. 132—152.

Journal’s Indexing:

UKRAINS'KYI VISNYK PSYKHONEVROLOHII

The Scientific and Practical Journal of Medicine

ДУ «ІНПН імені
П.В. ВОЛОШИНА
НАМН УКРАЇНИ»